TEVA-RIZATRIPTAN TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

RIZATRIPTAN (RIZATRIPTAN BENZOATE)

Sẵn có từ:

TEVA CANADA LIMITED

Mã ATC:

N02CC04

INN (Tên quốc tế):

RIZATRIPTAN

Liều dùng:

10MG

Dạng dược phẩm:

TABLET

Thành phần:

RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

SELECTIVE SEROTONIN AGONISTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0137841002; AHFS:

Tình trạng ủy quyền:

CANCELLED PRE MARKET

Ngày ủy quyền:

2015-10-16

Đặc tính sản phẩm

1
PRODUCT MONOGRAPH
Pr
TEVA-RIZATRIPTAN
rizatriptan benzoate tablets
5 mg and 10 mg rizatriptan (as rizatriptan benzoate)
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
Teva Canada Limited
Date of Revision:
30 Novopharm Court
November 30, 2011
Toronto, Ontario
M1B 2K9
Control Number: 127063, 150938
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND
PRECAUTIONS.........................................................................................
4
ADVERSE
REACTIONS.........................................................................................................
10
DRUG INTERACTIONS
.........................................................................................................
15
DOSAGE AND
ADMINISTRATION.....................................................................................
17
OVERDOSAGE
.......................................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 19
STORAGE AND
STABILITY.................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 21
PART II: SCIENTIFIC
INFORMATION....................................................................................
22
PHARMACEUTICAL
INFORMATION.................................................................................
22
CLINICAL
TRIALS............................................................................................